Xcout IntelSign inSubscribe

NanoEcho

NANECHHealth CareSweden

NanoEcho is a medical technology company that develops a diagnostic method for mapping the spread of rectal cancer to lymph nodes. The company's patented technology combines a magnetic field, iron oxide-based nanoparticles, and ultrasound to provide high-resolution imaging and improve treatment planning for healthcare providers.

Subscribe to see NanoEcho’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

NanoEcho at a glance

NanoEcho is a health care company headquartered in Sweden. Xcout tracks 6 named people at NanoEcho, including Fata Mrsic (CFO).

Industry
Health Care
Headquarters
Sweden
Ticker
NANECH

NanoEcho leadership

  • Fata MrsicCFO
  • Nils LöfgrenCTO
  • Björn LarssonTf. VD
  • Ulrika AxelssonKlinisk direktör
  • Johan FromholtzStyrelseledamot
  • Micael WikbergStyrelseordförande

NanoEcho competitors

A few of NanoEcho's closest competitors — see the full list of competitors and alternatives →

CELLBXHEALTH PLCCLBX · BiotechGuildford, United Kingdom
60% matchPublic

CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples. Beyond its core systems, CelLBxHealth offers the Portrait+ CTC Staining kit, a laboratory solution designed for the precise identification, characterization, and quantification of both epithelial and mesenchymal circulating tumor cells, boasting strong analytical sensitivity and specificity. Another key product is the CellKeep Slide, which facilitates CTC harvesting. The company extends its expertise through various laboratory services, including advanced CTC enrichment and liquid biopsy analysis. Its assay portfolio comprises Portrait Flex, an immunofluorescence assay for detecting epithelial, mesenchymal, and epithelial-to-mesenchymal transition states, as well as assessing DNA damage response. Additionally, CelLBxHealth provides Portrait PD-L1 for CTC evaluation and develops customized CTC assays. Strategic collaborations underpin some of its development efforts; it has partnered with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. involves utilizing a pan-cancer next-generation sequencing (NGS) panel. Originally established in 1994 as ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025 and operates from its base in Guildford, UK.

Market cap$20.4M
Employees119
CELLBXHEALTH PLC competitors & alternatives →

Get NanoEcho's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

NanoEcho — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on NanoEcho in Xcout Intel

  • 6 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →